This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised
by Zacks Equity Research
WST reports strong Q3 earnings and revenue growth, fueled by high-value products and margin expansion, and raises its 2026 sales and earnings outlook.
WSTPositive Net Change BDXNegative Net Change GMEDNegative Net Change GKOSPositive Net Change
earnings medical medical-devices
ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?
by Indrajit Bandyopadhyay
Intuitive Surgical's third-quarter sales surged 22%, outpacing procedure growth. Can system placements, new technologies and recurring revenues offset pricing pressures?
ISRGNegative Net Change BSXNegative Net Change GEHCNegative Net Change
medical medical-devices
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
ZBH heads into Q3 earnings with growth expected in Hips, S.E.T. and Technology & Data, while Knee sales face ongoing pressure.
ZBHNegative Net Change BDXNegative Net Change IDXXPositive Net Change PAHCNegative Net Change
earnings medical medical-devices
BSX Q3 Earnings Call Flags Growth Challenges Through 2027
by Zacks Equity Research
Boston Scientific faces a challenging 2027 as cybersecurity disruptions, EP and WATCHMAN weakness and China pricing pressures weigh on growth prospects.
BSXNegative Net Change
earnings medical-devices
2 Healthcare Technology Stocks for a Digital Health Boom
by Abhinab Dasgupta
GMED and STE offer exposure to healthcare technology growth, with projected 2026 EPS gains, attractive valuations and innovations in essential medical services.
STENegative Net Change GMEDNegative Net Change
medical-devices tech-stocks
Waters Gears Up to Report Q3 Results: How to Play the Stock?
by Zacks Equity Research
WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.
WATPositive Net Change BDXNegative Net Change IDXXPositive Net Change PAHCNegative Net Change
medical medical-devices
BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Boston Scientific's third-quarter revenues beat estimates, but contracting margins, weaker segment sales and reduced 2026 guidance weigh on shares.
BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change ELVNegative Net Change
earnings medical medical-devices
ProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?
by Zacks Equity Research
PDEX heads into fiscal Q1 earnings with strong medical-device sales and margin momentum, but customer concentration, a shrinking backlog and acquisition risks loom.
PDEXPositive Net Change EWPositive Net Change GMEDNegative Net Change GKOSPositive Net Change
medical medical-devices
SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?
by Zacks Equity Research
SYK's Q3 earnings may reflect strong hospital equipment demand and cybersecurity recovery, but supply constraints, vascular disruptions and margin pressures remain.
SYKNegative Net Change EWPositive Net Change GMEDNegative Net Change GKOSPositive Net Change
medical medical-devices
GEHC Q3 Earnings Beat Estimates on Strong Growth, '26 View Raised
by Zacks Equity Research
GE HealthCare's Q3 earnings and revenues beat estimates on strong segment growth and higher margins, driving raised 2026 guidance as shares gain 8.3%.
GEHCNegative Net Change ISRGNegative Net Change OPKNegative Net Change GMEDNegative Net Change
earnings medical medical-devices